When was Twist Bioscience founded?

Twist Bioscience was founded in 2013 and raised its 1st funding round 1 year after it was founded.

Where is Twist Bioscience located?

Twist Bioscience is headquartered in San Francisco, United States. It is registered at South Sanfrancisco,California.

Who is the current CEO of Twist Bioscience?

Emily Leproust of Twist Bioscience. They have also founded 2 companies and are angel investors in 2 startups.

How many employees does Twist Bioscience have?

As of Jul 31, 2026, the latest employee count at Twist Bioscience is 1304.

Is Twist Bioscience a funded company?

Twist Bioscience is a funded company, having raised a total of $321M across 11 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Feb 07, 2014.

When was the latest funding round of Twist Bioscience?

Twist Bioscience's latest funding was a $***** Series F round on Apr 02, 2018, with participation from 0 investor.

What is the annual revenue of Twist Bioscience?

Annual revenue of Twist Bioscience is between $100M and $500M as on Sep 30, 2025

Where does Twist Bioscience rank among its competitors?

Twist Bioscience ranks 3rd amongst 195 active competitors, of which 83 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Antheia, which secured $24M in Jan, 2026.

Who are the top competitors of Twist Bioscience?

Twist Bioscience's top competitors include Ginkgo Bioworks, Syngenta and Synthego. Among them, Antheia secured the most recent funding round in January, 2026.

Twist Bioscience - 2026 Company Profile, Team, Funding, Competitors & Financials

Twist Bioscience is a public company based in San Francisco (United States), founded in 2013 by Emily Leproust and Bill Peck. It operates as a Developer of a semiconductor-based DNA synthesis platform. Twist Bioscience has raised $321M in funding from investors like Fidelity Investments, Illumina and Paladin Capital. The company has 195 active competitors, including 83 funded and 32 that have exited. Its top competitors include companies like Ginkgo Bioworks, Syngenta and Synthego.

Company Details

Developer of a semiconductor-based DNA synthesis platform. The company has developed a proprietary silicon-based manufacturing process for the production of synthetic DNA which is used in diverse fields of medicine, agriculture, industrial chemicals and data storage. It offers synthetic genes, oligo pools, and NGS target enrichment to support research and innovation

Website: www.twistbioscience.com/
Social
Email ID: *****@twistbioscience.com
Registered Address: South Sanfrancisco,California

Key Metrics

Founded Year

2013

Location

San Francisco, United States

Stage

Public

Total Funding

$321M in 11 rounds

Latest Funding Round

Series F, Apr 02, 2018, $*****

Investors

Fidelity Investments & 40 more

Ranked

3^rd among 195 active competitors

Annual Revenue

$100M - $500M as on Sep 30, 2025

Employee Count

1,304 as on Jul 31, 2026

Investment & Acquisitions

iGenomX & 1 more

Similar Companies

Ginkgo Bioworks & 210 more

Exit Details

Public

View Twist Bioscience's full profile

Twist Bioscience is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
TWIST BIOSCIENCE, INC. CIN: 462058888 , United States, Active	Dec 31, 1999	-	542 (As on Dec 31, 2024)	-
TWIST BIOSCIENCE CORP CIN: 1581280 , United States, Active	Feb 03, 2013	$100M - $500M (As on Sep 30, 2025)	919 (As on Sep 30, 2023)	-
TWIST BIOSCIENCE UK LTD CIN: 13578466 , United Kingdom, Active	Aug 22, 2021	£1M - £10M (As on Sep 30, 2024)	18 (As on Sep 30, 2024)

Twist Bioscience got listed on Oct 31, 2018.

Click here to take a look at Twist Bioscience's IPO in detail

Twist Bioscience has raised a total funding of $321M over 11 rounds. Its first funding round was on Feb 07, 2014. Twist Bioscience has 38 institutional investors and 3 angel investors.

Here is the list of recent funding rounds of Twist Bioscience:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 02, 2018	3656398	Series F	1866925	7163075	3812334	5985818
Dec 29, 2017	6296190	Series E	5448992	4577789	2083431	9208752
Jun 14, 2017	2491794	Series E	2205238	8056987	3587130	Biomatics Capital & 6 more

Access funding benchmarks and valuations. Sign up today!

View details of Twist Bioscience's funding rounds and investors

The founders of Twist Bioscience are Emily Leproust and Bill Peck. Emily Leproust is the CEO of Twist Bioscience.

Here are the details of Twist Bioscience's key team members:

Emily Leproust: Co-Founder & CEO of Twist Bioscience and founder of 1 other company. They are also an angel investor in 2 startups.
Bill Peck: Former Co-Founder of Twist Bioscience.

View details of Twist Bioscience's Founder profiles and Board Members

Twist Bioscience's employee count trend

Twist Bioscience has 1,304 employees as of Jul 26. Here is Twist Bioscience's employee count trend over the years:

Employee count trend for Twist Bioscience

Uncover Twist Bioscience's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Twist Bioscience include Ginkgo Bioworks, Syngenta and Synthego. Here is the list of Top 10 competitors of Twist Bioscience, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Ginkgo Bioworks 2008, Boston (United States), Public	Autonomous labs for biotechnology, empowering scientists to design the living world	$796M	Viking Global Investors, T. Rowe Price & 53 others	81/100
2nd	Syngenta 2000, Basel (Switzerland), Acquired	Developer of technologies and sustainable farming practices for farmers	-	Analah Ventures, Europa	75/100
3rd	Twist Bioscience 2013, San Francisco (United States), Public	Developer of a semiconductor-based DNA synthesis platform	$321M	Foresite Capital, Fidelity Investments & 39 others	72/100
4th	Synthego 2012, Redwood City (United States), Acquired	Developer of CRISPR-engineered cell and gene therapies	$460M	8VC, Perceptive Advisors & 30 others	71/100
5th	Codexis 2002, Redwood City (United States), Public	Developer of high-performance enzymes for drug discovery	$111M	EDBI, Casdin Capital & 12 others	68/100
6th	AskBio 2001, Durham (United States), Acquired	Developer of AAV technologies for treating genetic and complex disorders	$235M	Vida Ventures, TPG & 4 others	68/100
7th	Amyris 2003, Emeryville (United States), Public	Developer of renewable products for industrial solutions	$487M	Temasek, Grupo Cornelio Brennand & 24 others	68/100
8th	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
9th	Asimov 2017, Boston (United States), Series B	Provider of integrated suite for advanced genetic design and manufacturing	$234M	Andreessen Horowitz, Horizons Ventures & 11 others	65/100
10th	Ansa Biotechnologies 2017, Berkeley (United States), Series B	Provider of DNA synthesis technology using enzymes	$177M	Northpond Ventures, Fifty Years & 17 others	64/100